Treatment of bone metastases in lung cancer: The actual role of zoledronic acid

Reviews on Recent Clinical Trials

Volumn 4, Issue 3, 2009, Pages 205-211

  Ricciardi, Serena ^a   De Marinis, Filippo ^a  

^a Thoracic Oncology Unit 1st   (Italy)

Author keywords

Bisphosphonates; Bone metastases; Lung cancer; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; FLUORODEOXYGLUCOSE F 18; IBANDRONIC ACID; MEDRONATE TECHNETIUM TC 99M; PAMIDRONIC ACID; PLACEBO; SIALOPROTEIN; STRONTIUM 89; ZOLEDRONIC ACID;

ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; BONE MARROW TOXICITY; BONE METASTASIS; BONE PAIN; CANCER SURVIVAL; CELL ADHESION; CLINICAL TRIAL; CONSTIPATION; COUGHING; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSPNEA; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCALCEMIA; INCIDENCE; JAW OSTEONECROSIS; LEG EDEMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MYALGIA; NAUSEA; OSTEOCLAST; OSTEOLYSIS; PATHOGENESIS; PATHOLOGIC FRACTURE; PATIENT MOBILITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; SPINAL CORD COMPRESSION; TUMOR LOCALIZATION; VOMITING; WEAKNESS;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; SURVIVAL ANALYSIS;

EID: 73349127846     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488709789957718     Document Type: Review

References (33)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2007; 57: 43-66.
2. Cersosimo RJ. Lung cancer: a review. Am J Health Syst Pharm 2002; 59: 611-42.
3. Mountain CF. A new international staging system for lung cancer. Chest 1986; 89(Suppl 4): 225S-33S.
4. Haus BM, Razavi H, Kuschner WG. Occupational and environmental causes of bronchogenic carcinoma. Curr Opin Pulm Med 2001; 7: 220-5.
5. Bunn PA, Jr. Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non small cell lung cancer:a review of the literature ad future directions. Clin Cancer Res 1998; 4: 1087-100.
6. Roodman GD. Mechanism of bone metastasis. N Engl J Med 2004; 350: 1655-64.
7. Colemann RE. Skeletal complications of malignancy. Cancer 1997; 80: 1588-94.
8. rd ed. New York: Churchill Livingstone 2004.
9. Guise TA, Mundy GR. Cancer and bone. Endocr Rev 1998; 19: 18-54.
10. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2: 584-93.
11. Janjan N. Bone metastases: approaches to management. Semin Oncol 2001; 28: 28-34.
12. Bellahcene A, Maloujahmounm N, Fisher LW, et al. Expression of bone sialoprotein in human lung cancer. Calcif Tissue Int 1997; 61: 183-8.
13. Ettinger DS. Treatment of bone metastases as a disease state in NSCLC. New directions in the treatment of lung cancer 2004; 1: 1-7.
14. Nackearts KL, Langer CJ, Harper PG, Manegold C, Ettinger DS, Kosmidis P. International Consensus panel recommendations for the diagnosis of bone metastases from lung cancer. J Thorac Oncol 2008; 3: S73.
15. Bury T, Bareto A, Daenen F, et al. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998; 25: 1244-7.
16. Cheon GJ, Chung J-K, Kim YK, et al. Diagnostic usefulness of F-18 FDG whole body PET in detection of bony metastases compared to TC-99m MDP bone scan. J Nucl Med 1999; 40: P96.
17. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonate in solid tumors:recommendations of an international expert pannel. Ann Oncol 2008; 19: 420-32.
18. NCCN Clinical Practice Guidelines in Oncology 2009. Available from: http\\:www.nccn.org/professionals/physician-gls/f-guidelines.asp.
19. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7: 377-87.
20. Woo SB, Hellstein JW, Kalmar JR. Narrative review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144: 753-61.
21. Khosla S, Burr D, Cauley J, et al. Bisphosphonates-associated osteonecrosis of the jaw: report of a task force of the American Society for bone and mineral research. J Bone Miner Res 2007; 22: 1479-91.
22. Stephens K, Kaura S, Botteman MF. Cost-effectiveness of zoledronic acid versus placebo in the management of skeletal metastases in lung cancer patients (LC pts): comparison across three European countries. J Clin Oncol 2009; 27 (Suppl; abstr 8081): 15s.
23. Delea TE, McKiernan J, Brandman J, et al. Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer. J Thorac Oncol 2006; 1: 571-6.
24. Lipton A. Efficacy and safety of intravenous bisphosphonates in patients with bone metastasis caused by metastatic breast cancer. Clin Breast Cancer 2007; 7(Suppl 1): S14-20.
25. Clemens MR, Fessele K, Heim ME. Multiple myeloma: effect of daily dichloromethylene bisphosphonates on skeletal complications. Ann Hematol 1993; 66: 141-6.
26. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with NSCLC: arandomized, phase III, double blind, placebo-controlled trial. J Clin Oncol 2003; 21: 3150-7.
27. Coleman RE. Should bisphosphonates be the treatment of choice for metastatic bone disease? Semin Oncol 2001; 28: 35-41.
28. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with NSCLC: arandomized, phase III, double blind, placebo-controlled trial. Cancer 2004; 100: 2613-21.
29. Hirsh V, Major PP, Lipton A, et al. Monitoring N-telopeptide of type I collagen levels for prognosis of clinical outcomes in patients with bone metastases from NSCLC receiving zoledronic acid. J Thorac Oncol 2008; 3: 228-36.
30. Kiagia M, Karapanagiotou E, Charpidou A, et al. Rapid infucsion of ibandronate in lung cancer patients with bone metastases. Anticancer Res 2006; 26: 3133-6.
31. Hatoum HT, Lin S, Lipton A, et al. The impact of zoledronic acid treatment on frequency of skeletal complications experienced and on follow up duration post diagnosis of bone metastasis in lung cancer patients. J Clin Oncol 2008; 26: Abstract 8106.
32. Hoskin PJ. Scientific and clinical aspects of radiotherapy in the relief of bone pain. Cancer Surv 1988; 7: 69-86.
33. Ebrahim A, Adedamola O, Rajagopalan S, Ravi SA. Strontium 89 in the treatment of pain due to diffuse osseous metastases: a university hospital experience. J Natl Med Assoc 2002; 94(8): 706-11.